InsiderClue
Stocks · Health care · Pharmaceutical Preparations

Cartesian Therapeutics, Inc.

RNAC Clue Score28
United States Fiscal year ends December CIK 0001453687 Results filed 5 Nov 2026
Add to watchlist

What the insiders did Net buying

Individual transactions

31
Insider
Date
Role
Action
Shares
Price
Amount
Metin Kurtoglu
10 Dec 2024
Chief Technology Officer
Sold after exercise
2,901
$24.35
$70.64K
Metin Kurtoglu
9 Dec 2024
Chief Technology Officer
Sold after exercise
4,539
$25.83
$117.26K
Metin Kurtoglu
9 Dec 2024
Chief Technology Officer
Sold after exercise
6,224
$25.26
$157.24K
Metin Kurtoglu
21 Nov 2024
Chief Technology Officer
Sold after exercise
32,789
$16.67
$546.56K
Metin Kurtoglu
20 Nov 2024
Chief Technology Officer
Sold after exercise
100
$18.09
$1.81K
Metin Kurtoglu
20 Nov 2024
Chief Technology Officer
Sold after exercise
5,600
$17.28
$96.76K
Metin Kurtoglu
19 Nov 2024
Chief Technology Officer
Sold after exercise
200
$19.50
$3.90K
Metin Kurtoglu
18 Nov 2024
Chief Technology Officer
Sold after exercise
17,728
$18.58
$329.43K
Metin Kurtoglu
18 Nov 2024
Chief Technology Officer
Sold after exercise
16,672
$18.19
$303.21K
Christopher M Jewell
15 Nov 2024
Chief Scientific Officer
Sold after exercise
16,065
$17.06
$274.09K
Milos Miljkovic
15 Nov 2024
Chief Medical Officer
Sold after exercise
20,000
$17.14
$342.89K
Metin Kurtoglu
15 Nov 2024
Chief Technology Officer
Sold after exercise
22,068
$17.20
$379.50K
Christopher M Jewell
14 Nov 2024
Chief Scientific Officer
Sold after exercise
17,500
$17.02
$297.82K
Christopher M Jewell
14 Nov 2024
Chief Scientific Officer
Sold after exercise
18,550
$16.34
$303.13K
Milos Miljkovic
14 Nov 2024
Chief Medical Officer
Sold after exercise
35,000
$16.13
$564.64K
Metin Kurtoglu
14 Nov 2024
Chief Technology Officer
Sold after exercise
4,000
$17.06
$68.26K
Metin Kurtoglu
14 Nov 2024
Chief Technology Officer
Sold after exercise
21,900
$16.33
$357.64K
David Siewers
20 Sep 2017
CFO and Treasurer
Sold after exercise
14,230
$20.00
$284.60K
David Siewers
20 Sep 2017
CFO and Treasurer
Sold after exercise
2,194
$20.00
$43.88K
Lloyd P. Johnston
3 Jul 2017
COO and SVP, R*D
Sold after exercise
5,859
$19.09
$111.83K
Lloyd P. Johnston
3 Jul 2017
COO and SVP, R*D
Sold after exercise
100
$19.74
$1.97K
David Siewers
30 Jun 2017
Chief Financial Officer
Sold after exercise
7,420
$20.00
$148.41K
David Siewers
29 Jun 2017
Chief Financial Officer
Sold after exercise
36
$20.00
$720.00
David Siewers
29 Jun 2017
Chief Financial Officer
Sold after exercise
9,616
$20.00
$192.32K
Peter Keller
27 Jun 2017
Chief Business Officer
Sold after exercise
4,595
$19.30
$88.68K
Lloyd P. Johnston
15 Jun 2017
COO and SVP, R*D
Sold after exercise
20,512
$17.00
$348.64K
Lloyd P. Johnston
17 Apr 2017
COO and SVP, R&D
Sold after exercise
13,205
$13.95
$184.21K
Lloyd P. Johnston
23 Jan 2017
COO and SVP, R&D
Sold after exercise
3,890
$14.17
$55.12K
Lloyd P. Johnston
23 Jan 2017
COO and SVP, R&D
Sold after exercise
11,110
$13.95
$154.98K
Takashi Kei Kishimoto
28 Dec 2016
Chief Scientific Officer
Sold after exercise
10,000
$17.55
$175.50K
David Abraham
21 Dec 2016
CCO, Gen.Counsel, Corp.Sec.
Sold after exercise
14,844
$18.00
$267.19K
Show all 244 transactions →

What was left out

Form 4 filings counted 335
Amendments (4/A) skipped 4
Filings about a different issuer 0
Unreadable filings 0
Joint filings 3
Sales on a Rule 10b5-1 plan 0
Sales straight out of an exercise 31
Sales at will 82
Transactions with no price 1
Shares from compensation/vesting 59,403,783
Sales filed before the plan box existed 65
History held since 23 Jun 2016